Anti-tnf

A group of biologic medicines that block TNF, a chemical messenger that drives inflammation. Includes infliximab and adalimumab.

Also called: tnf inhibitor, tnf blocker, anti-tnf alpha, antitnf, tnf-alpha inhibitor, tumour necrosis factor, tumor necrosis factor

Related words biologic combination therapy biologics infliximab biosimilar adalimumab

Topics Biologics and newer medicines

Questions people ask

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

What is upadacitinib (Rinvoq) and how is it different from biologics?

Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.

Sources

Can I have vaccines if I'm on azathioprine, biologics or other immunosuppressants?

Crohn's & Colitis UK says you should not have live vaccines, such as chickenpox, yellow fever or the children's nasal flu vaccine, while on an immunosuppressant. Non-live vaccines, such as the injected flu jab, COVID-19, pneumococcal and the Shingrix shingles vaccine, are safe. The NHS offers Shingrix to adults with a severely weakened immune system. Plan travel vaccines early with your IBD team, because some travel vaccines are live.

Sources

Is vedolizumab still used for Crohn's?

NICE still recommends vedolizumab (Entyvio) after an anti-TNF has failed or is unsuitable, and a Cochrane review found it works better than placebo. However, the 2025 BSG guideline no longer routinely suggests it for moderate to severe Crohn's, because the effect seen in trials was small. The review of the guideline says it may still suit selected people, after discussion with the IBD team.

Sources

Where to read more

Immunosuppressant precautions

Crohn's & Colitis UK Guide Oct 2023 For patients

Practical ways to lower the risks of medicines that suppress the immune system. You should not have live vaccines while on an immunosuppressant, but non-live vaccines such as the injected flu jab, COVID-19, Shingrix shingles and pneumococcal vaccines are safe. It explains checks for chickenpox immunity, the slightly raised risk of some cancers, especially skin cancer, and sun safety, plus food hygiene and travel precautions.

Topics Immunosuppressants Vaccinations and infections Cancer risk and screening Travel Biologics and newer medicines

Jargon explained immunosuppressant live vaccine non-live vaccine Shingrix pneumococcal vaccine JAK inhibitor anti-TNF

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Feb 2021 For professionals

European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.

Topics Children and young people Medicines Diet and nutrition Biologics and newer medicines

Jargon explained paediatric penetrating disease stricturing disease exclusive enteral nutrition anti-TNF immunomodulator therapeutic drug monitoring

Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Aug 2026 For professionals

The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.

Topics Children and young people Diet and nutrition Biologics and newer medicines Monitoring

Jargon explained anti-TNF therapeutic drug monitoring exclusive enteral nutrition endoscopic remission

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)

New England Journal of Medicine Study Jul 2024 Patients and professionals

A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.

Topics Biologics and newer medicines Research

Jargon explained non-inferiority endoscopic remission anti-TNF

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease

Cochrane Systematic review Aug 2019 Patients and professionals

Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.

Topics Immunosuppressants Surgery Research

Jargon explained postoperative recurrence low certainty evidence post-operative recurrence thiopurine 5-ASA anti-TNF

Fistulas

Crohn's & Colitis UK Guide Jan 2026 For patients

Explains why fistulas are more common in Crohn's, the different types (perianal is the most common), how they are found, including examination under anaesthetic and MRI, and treatment with medicines, setons and other surgery. It describes what living with a seton is like and gives clear urgent-help advice: contact your GP or 111 for fever, pain and pus, and 999 or A&E for possible sepsis.

Topics Around the bottom (perianal) Complications Surgery Urgent help Biologics and newer medicines

Jargon explained fistula perianal fistula seton examination under anaesthetic perianal abscess sepsis fistulotomy anti-tnf perianal metronidazole ciprofloxacin

A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease

Gut Guideline Sep 2014 For professionals

An international expert consensus on perianal fistulas in Crohn's. Key points: combine more than one test for an accurate picture, always drain infection before starting immune-suppressing treatment, anti-TNF medicines are the main treatment, and definitive surgical repair is only considered when the rectum is not inflamed.

Topics Around the bottom (perianal) Surgery Biologics and newer medicines

Jargon explained perianal fistula anti-tnf proctitis seton

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

NICE Guideline May 2010 For professionals

NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

NICE Guideline Aug 2015 For professionals

NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF TNF-alpha inhibitor patient access scheme moderately to severely active

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Search everything for "anti-tnf"